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Matrix metalloproteinases (MMPs) are a large family
of zinc-dependent endoproteases that catalyze
cleavage of extracellular matrix and nonmatrix pro-
teins. MMPs play a role in tissue remodeling, and
their uncontrolled activity is associated with number
of diseases, including tumor metastasis. Thus, there
is a need to develop methods to monitor MMP
activity, and number of probes has been previously
described. The key problem many probes encounter
is the issue of selectivity, since 23 human MMPs,
despite playing different physiological roles, have
structurally similar active sites. Here, we introduce
the halogen bonding concept into the probe design
and show that the probe containing iodine exhibits
an unprecedented selectivity for MMP-9. We provide
structure-based explanation for the selectivity, con-
firming that it is due to formation of the halogen
bond that supports catalysis, and we highlight the
value of exploring halogen bonding in the context
of selective probe design.
INTRODUCTION
Human matrix metalloproteinases (MMPs) constitute a family of
23 structurally related extracellular/cell-surface-anchored zinc
endoproteases (Fanjul-Ferna´ndez et al., 2010). MMPs cleave
extracellular matrix proteins and thereby mediate both normal
and pathological tissue remodeling processes (Mott and Werb,
2004; Sternlicht andWerb, 2001). Their functions extend beyond
the matrix, and MMPs act as regulators of diverse processes by
cleaving nonmatrix extracellular proteins (Morrison et al., 2009;
Parks et al., 2004). Consequently, there have been substantial
efforts to detect and inhibit uncontrolled MMP activity
under various pathological conditions and to exploit them as
biomarkers or therapeutic targets (Fingleton, 2007; Fu et al.,
2008). Various protocols have been used to detect MMP activity.
The simplest is based on the use of synthetic fluorescence reso-
nance energy transfer (FRET) substrates as probes that fluo-
resce on cleavage. However, such substrates do not display
substantial specificity, despite significant efforts to develop
selectivity; this limits their value because any cleavage activity
cannot be attributed unambiguously to a particular MMP (Akers
et al., 2012; Jabaiah and Daugherty, 2011; Jiang et al., 2004;408 Chemistry & Biology 21, 408–413, March 20, 2014 ª2014 ElsevieKridel et al., 2001). The inability to discriminate between different
MMPs also hinders the design of highly selective inhibitors
(Yiotakis and Dive, 2008). These difficulties are, in large part,
due to the substantial structural similarities between the active
sites of the various MMPs (Devel et al., 2010). Here, we describe
the exploitation of the unique properties of halogens to mediate
diverse and highly specific interactions within the active sites of
proteins to allow discrimination between closely related MMPs.
RESULTS
We used the peptide sequence of a fluorogenic peptide
commonly used to monitor MMP activity as the basis for our
FRET substrate probe. In this substrate probe, the P1
0 position
is occupied by a leucine residue that partially fills the deep S1
0
channel in the active sites of all MMPs. The unusual shape of
the MMP S1
0 cavity can be exploited to develop new probes
with long and bulky side chains in the P1
0 position; these side
chains can be adapted to fit the S1
0 cavity of a particular MMP
(Figure 1A). The presence of unusual amino acids in the sub-
strate sequence may also contribute to selectivity by preventing
cleavage by other proteases possessing shallower S1
0 cavities.
While the catalytic efficiency of a set of five MMPs to cleave
such probes was high (compounds 1 to 4; kcat/KM: 1 3
105 M1 , s1 to 63 105 M1 , s1), these probes discriminated
only poorly the different MMPs (Figure 1B).
Several carbonyl groups of the protein polypeptide chain point
into the cavity of the MMP S1
0 pocket. As halogens can interact
with electron-rich oxygen atoms such as those in carbonyl
groups (i.e., halogen bonding or X-bonding) (Auffinger et al.,
2004; Parisini et al., 2011), we evaluated substrate probes with
P1
0 phenylalanine analogs halogenated in the paraposition (X =
F, Cl, Br, I). The catalytic efficiency of MMP-9 to cleave these
probes increased in the order F < Cl < Br < I (compounds 5 to
8) (Figure 1C), which correlated with the predicted halogen
X-bond strength (Politzer et al., 2010). Probe 8 was cleaved 23
times more efficiently than probe 5 (Table S1 available online)
and also more efficiently than probes 1–4 by MMP-9. Assayed
on five MMPs, probe 8 also displayed a better selectivity profile
(Figure 1C). These observations reveal that a single atom, point-
ing toward the S1
0 cavity and positioned away from the catalytic
zinc ion, can affect transition-state stabilization in this enzymatic
system. The ability of probe 8 to discriminate between MMP-2
and MMP-9, in particular, is remarkable because their enzyme
cavities are structurally highly similar. For MMP-2, the replace-
ment of fluorine by iodine in the probe only increases the cata-
lytic efficiency 3-fold, while, for MMP-9, this modification resultsr Ltd All rights reserved
Figure 1. Chemical Structure and Selectivity of Probe Substrates 1
to 8 for MMPs
(A) Generic chemical structure of substrate probes; the blue arrow indicates
the peptide bond cleaved by MMPs, and the simple arrow indicates the P1
0
position of the probe substrate, with the its side chain plugging in the S1
0 cavity;
the bold letter R refers to the side chain of the probes.
(B) Increasing the size of the side chain (indicated by the bold letter R) in the P1
0
position involved a modest improvement of the probe substrate selectivity
(compounds 1 to 4) toward MMPs (color coded).
(C) In contrast, the nature of the halogen atom in compounds 5 to 8 is a
determinant for probe selectivity and allowed the identification of a probe
substrate selective for MMP-9. Data are means ± SEM.
See also Tables S1 and S4.
Figure 2. Crystal Structures of MMP-9 Complexes with Probe
Substrates 5 and 8
(A) Surface representation of an MMP-9 catalytic domain with probe substrate
8 indicated by a pink ball and stick, the P1
0 p-iodo-phenylalanine side chain
entering the S1
0 subsite can be seen through the transparent protein surface.
Oxygen, red; nitrogen, blue.
(B) Probe substrate 8 establishes seven hydrogen bonds with the MMP-9
active site, with the carbonyl of the scissile peptide bond interacting with the
zinc ion.
(C) Superimposition of probe substrates 5 and 8 as bound to MMP-9 shows
overlap between probes, except for the phenyl ring of probe 8, which pene-
trates slightly deeper into the pocket, and, because the carbon-iodine bond is
longer than the carbon-fluorine bond, the iodine (indicated in purple; fluorine is
indicated in cyan) is positioned further down in the S1
0 cavity.
See also Table S2.
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In addition, for MMP-2, the highest catalytic efficiency was
observed for the probe containing bromine than for the probes
containing the other halogens. Thus, despite the substantial
similarity between the active sites of MMP-2 and MMP-9, the
use of halogens allows clear discrimination between these
two MMPs.
The iodine atom is larger than the fluorine atom andmay there-
fore fill the S1
0 cavity of MMP-9 better, leading to the observed
difference in enzymatic efficiencies. However, the results with
probes 1 to 4 are inconsistent with this explanation: bulky groups
on probes 1 to 4 that fill this cavity equally well were not selective
(Figure 1B). It is, therefore, likely that the observed differences
are associated with specific interactions involving the halogen
atoms.Chemistry & Biology 21, 4Crystallization proved to be difficult, but wewere able to deter-
mine the crystal structures of MMP-9 in complex with probes 5
and 8. Both probes were crystallized with an inactive mutant of
the minicatalytic domain of MMP-9, in which the catalytic gluta-
mate residue was replaced by an alanine (Glu227 / Ala227) to
avoid probe cleavage. This mutation has been widely used to
crystallize MMP-9 (Tochowicz et al., 2007), as it also prevents
protease autolysis without affecting the protein structure. The
two MMP-9 complexes were crystallized in the same lattice
with two molecules in the asymmetric unit (Table S2). The
MMP-9:8 complex is a structure of MMP-9 with an intact peptide
substrate spanning the entire active site from subsites S3 to S3
0
(Figure 2A). The probe adopts an elongated conformation, form-
ing a b strand within the active site stabilized by seven hydrogen
bonds, with the scissile peptide pointing above the zinc atom
(Figure 2B), near the Ala227 residue (Figures S1C and S1D), and
with the para-iodo-Phe residue side chain pointing into the S1
0
cavity (Figure 2A). The iodine atom in this cavity is in close prox-
imity to a water molecule, so the I—OW distance (OW represents
the oxygen atom in water) is short (2.4 and 2.71 A˚ for molecules A
and B, respectively), much shorter than the sum of their van der
Waals radii (3.55 A˚) (Figure 3A; Figures S1A and S1B); and the
C-I—OW angles are 163
 and 172 (for molecules A and B,
respectively) (Figure 3A; Figures S1A–S1D; Table S3). The OW
is also in hydrogen bond distance of the carbonyl oxygen atom
of the Arg249 peptide bond: the OW—OCArg distance is 2.48
and 2.78 A˚ for molecules A and B, respectively (Figure 3A;08–413, March 20, 2014 ª2014 Elsevier Ltd All rights reserved 409
Figure 3. Details of the Interactions
Involving the Halogens in the MMP-9
Active Site
(A) Left: molecular representation of the crystal
structure of the MMP-9:8 complex with the
red dashed line showing the I (purple)—
OW(red ball)—H bridge involving the carbonyl of
Arg249. Probe 8 is indicated by a pink ball and
stick, and the zinc atom is indicated as a big purple
sphere. Right: electron density map around the
iodine atom (gray ball) and the water molecule
(pink crossed sphere). The d1 and d2 distance
values (left panel) are reported. Oxygen, red;
nitrogen, blue.
(B) Left: molecular representation of the crystal
structure of the MMP-9:5 complex showing the
fluorine atom (cyan) relative to a water molecule
(red sphere), which is within hydrogen bonding
distance from the Leu243 carbonyl. The zinc atom
is indicated as a big purple sphere. Right: electron
density map around the fluorine atom (gray ball)
and the water molecule (pink crossed sphere). The
d1 and d2 distance values (left panel) are reported.
See also Figure S1 and Table S3.
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a stabilizing bridge between the iodine of probe 8 and the
carbonyl oxygen of Arg249 in MMP-9 (iodine-water-hydrogen
[I-W-H] bridge, with a distance I—OW—OCArg249 = 4.4 A˚ [longer
dashes indicate noncovalent bonds; shorter dashes indicate
covalent bonds]). Other geometric measures characterizing
this halogen-water-hydrogen bridge are reported in Table S3.
The values fit well with those previously reported for I-W-H
bridges formed between proteins and small ligands (Zhou
et al., 2010).
To determine whether this halogen X-bonding is specific for
the iodine atom, we also looked at the MMP-9:5 complex. The
structures MMP-9:8 and MMP-9:5 were isomorphous, and
superimposing the structures of the two protein complexes
revealed a near-perfect fit (Figure 2C). The positions of the two
probes coincide with each other with only minor deviations,
except for the p-iodo-Phe and p-fluoro-Phe side chains. The
iodine atom of probe 8 penetrates deeper than the fluorine of
probe 5 due to the longer iodine-carbon bond length and a
slightly different positioning of the benzyl ring (Figure 2C). With
the fluorine probe, as for the iodine probe, a water molecule
was observed near the halogen, but at a different position; as a
result, the F—OW distances were 3.1 to 3.18 A˚ in molecules A
and B and thus longer than the sum of the F and OW van der
Waals radii (2.75 A˚) (Table S3). This is consistent with the positive
electrostatic potential (the s-hole) of fluorine being smaller than
those of other halogens, limiting its interactions with electron-
rich atoms (Politzer and Murray, 2013). The water molecule410 Chemistry & Biology 21, 408–413, March 20, 2014 ª2014 Elsevier Ltd All rights reservedclosest to the fluorine atom establishes
a hydrogen bond with the carbonyl of
Leu243, Tyr245, and Ala242, instead of
Arg249 (Figure 3B; Figures S1E and S1F).
In the MMP-9:8 complex, the electron
density map shows overlap between the
electron clouds of the iodine atom andthose of the oxygen atom of the interacting water molecule, a
feature not shared by the fluorine probe 5 (Figures 3A and 3B).
The FRET probe described in this study can be used in various
conditions in vitro to detect MMP-9 activity. When probe 8 was
assayed on a large set of MMPs, it still displayed selectivity
toward MMP-9 (Figure 4). Under the experimental conditions
used, in 30 min, almost all of the probe 8 was cleaved by
MMP-9, whereas, for other MMPs, only a faint cleavage was
observed (Figure 4; Figure S2). MMP-9 cleaves probe 8 with a
kcat/KM value of 6.53 10
6 M1 , s1, which is among the highest
catalytic efficiencies reported to date for an MMP FRET sub-
strate probe. Therefore, assays with probe 8 have a detection
threshold of 0.5 fmol of MMP-9 (reaction time, 30 min and in a
volume of 100 ml). The kinetic parameters for the cleavage of
probes 8 and 5 by MMP-9 were determined: the presence of
the iodine atom rather than a fluorine atom increases both the
KM and kcat values (Table S4). We also studied the cleavage of
probe 8 by five cathepsins, as these enzymes are commonly
overexpressed in pathological tissues (Verdoes et al., 2013).
Capthesins S, B, and V did not cleave the probe under the exper-
imental conditions used, while cathepsins K and L displayed
weak cleavage activities (Figure 4).
DISCUSSION
Despite significant advances in the study of halogen X-bonding
in material chemistry, these interactions are still underexploited
for the design of potent and selective biomolecule ligands
Figure 4. Catalytic Efficiency of a Set of Nine MMPs and Five
Cathepsins for the Cleavage of Probe Substrate 8
For cathepsins labeled with an asterisk, no cleavage was observed. Experi-
mental conditions: 50 mM Tris-HCl buffer, pH 6.8, 10 mM CaCl2 at 25
C,
0.5 mM probe 8, and 0.3 nM MMPs and cathepsins. Data are means ± SEM.
See also Figure S2 and Tables S1 and S4.
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tions and their thermodynamic stability may both be useful for
drug design. The contributions of X-bonds to potency and selec-
tivity have been reported for a small number of protein-ligand
complexes. In many cases, these effects on potency are associ-
ated with the distance between X (halogen) and B (a negative
site, like O) in R-X—B, as determined from crystal structures,
being shorter than the sum of the X and B van der Waals radii
(Baumli et al., 2010; Hardegger et al., 2011). Experimental
data of this type are essential for validating computational
approaches and for improving our understanding of these inter-
actions. Fewer experimental data are available for halogen-
water-hydrogen bridges than X-bonds, with only six relevant
protein complex crystal structures being available; all involve
an iodinated ligand in the Protein Data Bank (PDB), and the
contribution of this interaction to the ligand affinity has not
been quantified (Zhou et al., 2010). The interactions observed
in the crystal structure of MMP-9:8 complex are consistent
with the presence of an I—Ow—H bridge. However, it should
be noticed that the B-factor value of the water molecule involved
in this bridge indicates a residual mobility, as at the Arg249
carbonyl group level, in comparison with the iodine atom B-fac-
tor value (Figure S1D). The structural differences observed
between the complexes of probes 5 and 8 with MMP-9 indicate
that the difference in the catalytic efficiency exhibited by MMP-9
when cleaving the probes may be due to a stabilizing contribu-
tion from the I—OW—H bridge or the I—Ow halogen bond. If
true, the 23-fold difference in the catalytic efficiency of MMP-9
toward probes 5 and 8 implies that these interactions corre-
spond to a difference in free energy of 1.88 kcal/mol (DDG) in
the transition state structure stabilization between probes 5
and 8. Although the MMP-9:5 and MMP-9:8 complexes with
intact peptide bonds are not strictly equivalent to the transi-
tion-state structures, most differences between these two states
should take place at the substrate backbone level, and less in theChemistry & Biology 21, 4depth of the S1
0 cavity, because side chain movements in the P10
position are restricted by a narrowing at entrance of the cavity.
Obviously, the contribution of additional factors cannot be
excluded. It would be informative to determine why X-bonding
or analogous I—OW—H bridges are not operative in other
MMPs, given that their S1
0 cavities share many structural similar-
ities. There may be local structural or dynamic reasons why the
formation of specific interactions with iodine may be possible
for probe 8 only in MMP-9; indeed, the residue in position 249
(Arg249 in MMP-9) is not conserved between MMPs and belongs
to the S1
0 loop, a loop being only poorly conserved between
MMPs. Efforts to obtain crystal structures with other MMPs
failed. For Glu / Ala mutants of both MMP-12 and MMP-8,
products corresponding to cleavage of the substrate were
observed in their active sites, suggesting that additional muta-
tions are required to decrease residual MMP activity further. It
would be useful to obtain thermodynamic data to determine
energy differences (enthalpy and entropic contribution) for the
formation of the complexes of MMP-9 with probes 5 and 8. As
recently reported, the entropic contributions to the total free
energies may depend on the halogen (Carter et al., 2013). Here
again, residual activity of the MMP-9 mutant in solution at
25C has prevented us from obtaining the expected data.
SIGNIFICANCE
Our results suggest that halogen bonding could be exploited
as a new avenue for developing probes or inhibitors with
improved selectivity toward MMPs. Both direct and indirect
halogen bonding should be explored, and the MMP struc-
tures reported here provide useful hints on how to achieve
these objectives. The particular probe sequence used in
this work for MMP-9, a key MMP involved in many human
disorders (Vandooren et al., 2013), could also be used for
various applications, including detection of MMP-9 activity
in vitro and in vivo by imaging, by inserting this sequence
into probes designed for such applications (Jiang et al.,
2004; Ryu et al., 2013).
EXPERIMENTAL PROCEDURES
Peptide Synthesis and Characterization
Commercial reagents were used as received without additional purification.
Solvents were of the reagent grade available. Fmoc amino acids, rink amide
resin, universal polyethlene glycol (PEG) NovaTag resin, and 1-[(1-(cyano-2-
ethoxy-2-oxoethylideneaminooxy) dimethylaminomorpholino)] uronium hexa-
fluorophosphate (COMU) were from Novabiochem. N-a-Fmoc-N-b-(2,4-dini-
trophenyl)-L-2,3-diaminopropionic acid, Fmoc-4- fluoro-L-phenylalanine,
and (7-methoxycoumarin- 4-yl)acetyl were fromBachem. Fmoc-4-nitropheny-
lalanine, Fmoc-4-bromo-L-phenylalanine, Fmoc-4-chloro-L-phenylalanine,
and Fmoc-4-(phenoxy)-L-phenylalanine were from PolyPeptide. Fmoc-
4-iodo-L-phenylalanine, Fmoc-propargyl glycine, 1-hydroxybenzotriazole,
dichloromethane (DCM), N,N-dimethylformamide (DMF), anhydrous
tetrahydrofuran, phenylboronic acid, tetrakis(triphenylphosphine)palladium,
4-bromobiphenyle, sodium ascorbate, sodium azide, N,N-dimethylethylenedi-
amine, copper iodide, 2-amino-2-(hydroxymethyl)-1,3-propanediol (Tris
base), and calcium chloride (CaCl2) were from Sigma-Aldrich. N,N-diisoproy-
lethylamine (DIPEA) was from Fluka.
Analytical and preparative reverse-phase high-performance liquid chroma-
tography (HPLC) separations were performed on a Shimadzu HPLC system
using analytical AIT C8 Kromasil (250 3 4.6 mm; 100 A˚; gradient, 0 to
20 min/0 to 100%B; flow rate, 1 ml , min1) and semipreparative AIT C808–413, March 20, 2014 ª2014 Elsevier Ltd All rights reserved 411
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3 ml , min1) columns; and UV detection was performed at 215 nm at
330 nm. Solvent systems used were as follows: A: 0.1% trifluoroacetic acid
(TFA) in water; and B: 0.09% TFA in acetonitrile.
A 4800 spectrometer MALDI-TOF/TOF Proteomics Analyzer (Applied Bio-
systems) was used for mass spectrometry analysis of samples. a-Cyano-4-
hydroxycinnamic acid from Fluka was used as the organic matrix for mass
spectrometry analysis. Cyanine substrate was analyzed on a hybrid instrument
LTQ-ORBITRAP-ThermoElectron Corporation. UV measurements were per-
formed with a Shimadzu spectrophotometer (UV 1800).
Human MMPs (MMP-2, MMP-3, MMP-7, MMP-8, MMP-9, MMP-12, MMP-
13,MMP-14) andhumancathepsinsB, L, S, andVwere fromR&DSystems; hu-
man cathepsin K was from Calbiochem. MMP activation was performed by
treatment with p-aminophenylmercuric acid according to supplier indication.
Probe Synthesis
Probes were synthesized by Fmoc solid-phase synthesis strategy. Rink amide
resin was swelled with DCM (15 min). Removal of Fmoc was performed using
piperidine in DMF (20% piperidine, 2 3 2 min, 1 3 5 min), then Fmoc-Arg-OH
was incorporated into the solid support, using COMU as a coupling agent for
30 min (6 equivalents of amino acid, 5.8 equivalents of COMU, 12 equivalents
of DIPEA in DMF). A second coupling was performed for 20 min (3 equivalents
of amino acid, 2.8 equivalents of COMU, 6 equivalents of DIPEA in DMF). After
sequential incorporation of each amino acid, the fluorophore (7-methoxycou-
marin-4-yl)acetyl was coupled (6 equivalents of amino acid, 5.8 equivalents of
COMU, 12 equivalents of DIPEA in DMF) for 1 hr, and a second coupling was
performed. After cleavage of the resin (TFA/triisopropylsilane/H2O, 95/2.5/2.5,
4 hr) and freeze-drying of the cleavage solution, crude product was purified by
HPLC (0%–100%B in 30 min). After freeze-drying of the purified fractions,
DMSO was added and probe concentration was determined by UV (l =
333 nm; ε = 21,470 cm1 M1). The product purity was assessed by analytical
HPLC and mass spectrometry analysis. Further details on synthesis and
characterization of probes are provided in the Supplemental Information.
Enzyme Assays
Enzyme inhibition assays were carried out in 50 mM Tris-HCl buffer, pH 6.8,
10 mM CaCl2, at 25
C. The assays were performed in black 96-well plates
(nonbinding surface plates; Corning Costar Catalog No. 3651). Progress
curves were monitored by recording the increase in fluorescence resulting
from substrate cleavage (lexcitation = 320 nm, lemission = 405 nm). The condi-
tions of a typical experiment were 100 ml of buffer and 1–5 nM of MMP or
cathepsins (R & R Systems). The reaction was then initiated by addition of
0.5 mM of substrate (stock solution of 100 mM of substrate in DMSO). Data
were collected for 1 hr. The kcat/KM values were determined from first-order
full-time reaction curves (S < < KM; S = 0.5 mM) and fitted with the integrated
Michaelis-Menten equation by nonlinear regression: P = S0(1  exp(kt)),
where P is product concentration; S0 is substrate concentration at
t (time) = 0; exp is exponential; k is (kcat/KM) , E; and E is enzyme concentration
(Table S1). The kinetic parameters KM and kcat were estimated according to the
direct linear plot method (Table S4).
Structural Studies
Protein Preparation
The expression and purification for the mostly inactive mini-MMP-9 catalytic
domain (MMP-9, Glu227 / Ala227, MMP-9A) used in the crystallographic
studies has been described elsewhere (Antoni et al., 2013). In brief, the
synthetic gene used for the catalytic domain of human MMP-9 comprises res-
idues Gly106–Gly215 and Gln391–Gly444, without the fibronectin domains
and with the catalytic glutamate mutated to alanine (Tochowicz et al., 2007).
Plasmids were propagated in the Escherichia coli strain XL1-Blue, and the
recombinant catalytic domains were expressed in E. coli BL21 (DE3 star) cells.
After induction, the cells were harvested by centrifugation and the pellets were
resuspended. The cell suspension was disrupted and then centrifuged. The
pellets were washed and then dissolved again. Refolding, purification, and
dialysis steps were carried out as described elsewhere (Antoni et al., 2013).
Acetohydroxamic acid (AHA; 120 mM) was added to prevent self-degradation
during concentration with an Amicon-stirred ultrafiltration cell with an ultrafil-
tration regenerated-cellulose disk membrane (3,500 Da molecular weight cut-412 Chemistry & Biology 21, 408–413, March 20, 2014 ª2014 Elsevieoff; Millipore). The enzyme was concentrated in the range of 0.182–0.421 mM
in a buffer consisting of 3 mMCaCl2, 120 mMAHA, 200 mMNaCl, 20 mM Tris-
HCl, pH 7.5. By SDS-PAGE, the purity can be evaluated to be higher than 95%.
Crystallization and Structure Determination
The crystallization trials were carried out by sitting vapor diffusion with 1 ml
equivolumetric drops of protein substrate and reservoir solution using
CrysChem plates that were equilibrated in a cooled incubator at 20C. Probe
8 was added with 1.8 stoichiometric excess (0.33 mM) to the enzyme at
0.182 mM used in the crystallization studies. The reservoir solution consisted
of 10% PEG 20K, 100 mM MMT buffer (mixed L-malic acid, MES, and Tris in
the ratio 1:2:2; 75% at pH 4 and 25% at pH 9), 800 mM NaCl, 200 mM SrCl2,
and 0.01% azide (Newman, 2004). Trials with probe 5 set up as for probe 8
gave crystals of the product complex. The complex of the intact substrate
could be obtained when drops of probe 5 were streak seeded (Stura and
Wilson, 1991) immediately after setting up the drops with crystals of probe 8
with the intact substrate, resulting in crystals that diffracted to only 2.7 A˚.
The diffraction limit could be increased to 1.85 A˚ with protein-inhibitor solution
prepared with 0.42 mMMMP-9, 1 mM probe, 120 mM AHA, 17 mM SrCl2, and
1%NaN3 (Table S2). The crystals of theMMP-9A:probe 8 complex were trans-
ferred to a premixed cryo-protecting solution based on condition C2 from
CryoProtX (Molecular Dimensions) (as described in Vera and Stura, 2013) for
a few seconds, and then they were picked up into a loop and finally cryo-
cooled in liquid nitrogen (Table S2). For the crystals of the MMP-9A:probe 5,
the best diffraction was obtained using a new evolution of the premixed solu-
tions also including 5%dioxane (Table S2) picked upwith a litho-loopmounted
and flash-cooled in liquid nitrogen usingmagnetic SPINE-compatible cryovials
for data collection at synchrotron facilities. Data for theMMP-9A-probe 8 com-
plex were collected at the Soleil Synchrotron Facility on beamline Proxima 1 at
100 K from a single crystal and reduced using XDS (Kabsch, 2010) and the
script ‘‘xdsme’’. The crystal belongs to the space group P212121 with the
following cell parameters: a = 34.2 A˚, b = 57.4 A˚, and c = 172.0 A˚ diffracting
to 1.7 A˚ resolution (Table S2). The structure was solved by molecular replace-
ment with MOLREP (Vagin and Teplyakov, 2010), using the coordinates of the
cleaved complex and refined with REFMAC5 (Murshudov et al., 2011) and
phenix.refine (Adams et al., 2010) to improve the solvent model. Restraints
for the 7-methoxycoumarin-4-acetic acid and the (2S)-2-ammonio-4-[(2,4-di-
nitrophenyl)amino]propanoate probe components were created using the
monomer library sketcher from the CCP4 program suite (Winn et al., 2011).
The model was rebuilt in the electron density in COOT (Emsley et al., 2010).
The data for the MMP-9A:probe 5 complex were collected at the European
Synchrotron Radiation Facility, on beamline ID23-1 from a single crystal, and
the data were processed automatically using XDS (Kabsch, 2010). The crystal
belongs to the orthorhombic P212121, with cell parameters almost identical to
those of crystals of MMP-9A:probe 8 (Table S2). Being isomorphous with the
crystal structure of probe 8 in complex withMMP-9, after rigid body refinement
with REFMAC5 (Murshudov et al., 2011) and the replacement of the iodo-
phenyl by a fluorophenyl moiety, the structure was improved with cycles in
phenix.refine (Adams et al., 2010) and COOT. The electron density for the sub-
strate in both molecules in the asymmetric unit is well defined.
Crystallization Strategies
Several crystallization attempts were carried out over a period of more than
12 months before high-resolution X-ray structures could be obtained with
both intact substrates. Although the catalytic glutamate has been mutated
to alanine, the enzyme remained catalytically competent over the period of
1–4 days needed to grow large crystals suitable for crystallographic studies.
High concentrations of AHA (120 mM) were found to be relatively ineffective
to prevent cleavage. Success was achieved with probe 8 when strontium
was added to the crystallization precipitant so that it could replace partially
two of the more labile calcium ions that contribute to enzyme stabilization.
The same strategy allowed data to be collected for probe 5 but only to
2.7 A˚, probably because of the heterogeneous presence of the cleavage prod-
uct. The resolution could be improved to 1.85 A˚ after NaN3 was added to the
protein-substrate mix before crystallization.
ACCESSION NUMBERS
The crystal structure data for the MMP-9 in complex with probe 8 and probe 5
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